AIDS drugs: resistance emerging in parts of Africa – study

RESISTANCE to AIDS drugs, a problem that has been widely feared over the last decade, is growing in parts of Africa but should not hamper the life-saving drug rollout, researchers reported on Monday.

Tiny genetic mutations that make HIV immune to key frontline drugs have been increasing in eastern and southern Africa, something that should be a clear warning to health watchdogs, they said.

“Without continued and increased national and international efforts, rising HIV drug resistance could jeopardize a decade-long trend of decreasing HIV/AIDS-related illness and death in low- and middle-income countries,” they said.

The study, published in The Lancet, is funded by the Bill and Melinda Gates Foundation and the European Union (EU).

It is the widest-ever analysis of a risk that has haunted AIDS campaigners since 2003, when drugs started to be rolled out to poorer countries that are home to more than 90 percent of people with the AIDS virus.

The nightmare is that — as with bacteria which become resistant to antibiotics — strains of HIV will emerge that will blunt the armoury of antiretrovirals, leaving millions defenceless.

Silvia Bertagnolio from the UN’s World Health Organisation and Ravindra Gupta at University College London looked at published cases of HIV resistance and supplemented this with data from the WHO itself.

Over eight years, prevalance of resistant virus in untreated people soared from around one percent to 7.3 percent in eastern Africa, and from one percent to 3.7 percent in southern Africa, they found.

Similar rates of 3.5-7.6 percent were also found in western and central Africa, Latin America and the Caribbean.

The difference, though, is that they remained quite stable throughout this period, and did not experience such a big rise.

The mutations were found in strains of HIV-1 virus that made them resistant to a class of drugs called non-nucleoside reverse transcriptase inhibitors, or NNRTIs.

These are the first-option treatments for HIV infection and are also used to prevent transmission of the virus from a pregnant woman to her foetus.

If a patient is resistant to the drug, the risks of sickness and death rise in line with levels of virus.

Further treatment options do exist beyond NNRTIs, but these second-line regimens are often far costlier.

The paper says countries should step up monitoring of HIV resistance and take steps to guard against start-stop treatment that fuels the problem.

They can do this by ensuring that drug supplies are not interrupted and by beefing up monitoring of patients to encourage them to follow the daily pill-taking regimen.

Despite the concern, the rollout should carry on, says the paper.